3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors

3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors

The invention relates to a compound of Formula Ior a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Witkos, Faith Elizabeth, Cowdrey, Connor James, Doerner Barbour, Patrick Michael, Moreno, David Austin, Dahlke, Joshua Ryan, Kellum, Alex Andrew, Knapp, Ellen Margaret, Clark, Wesley Dewitt, Fulton, Jennifer Lynn, Blake, James Francis, Boys, Mark Laurence, Ren, Li, O'Leary, Jacob Matthew, Allen, Shelley, Blanche, Sydney Taylor
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The invention relates to a compound of Formula Ior a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.